“One of the most important resources held by the UK health system is the data generated by the 65 million people within it,” wrote John Bell, regius professor of medicine at Oxford University, in the government’s life sciences industrial strategy published in August. “The development of platforms to enable de-identified health data to be appropriately used to research and develop technologies would be of great benefit to patients, to those managing the NHS, and to researchers attempting to develop new therapies or improve NHS care,” continued Bell, who is also chairman of the Office for the Strategic Coordination of Health Research, which coordinates the research of the National Institute for Health Research and the Medical Research Council. NHS records, he argued, are uniquely suited to helping develop powerful algorithms that could transform healthcare and seed an “entirely new industry” in diagnostics based on artificial intelligence (AI). Bell’s strategic goal for the NHS is to develop 50 separate programmes in collaboration with industry over the next five years, including large scale data analysis. And yet—at a panel discussion organised by Stanford Medicine and the Royal College of Physicians that asked, “Are data and analytics the new medicine?” and just five days after Bell’s strategy was published—experts from both sides of the Atlantic warned that serious problems lie ahead.
Read the full BJM article written by Stephen Armstrong, free lance journalist.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
